✦ LIBER ✦

Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy

✍ Scribed by Michael B. Atkins

Book ID: 107576779
Publisher: Springer US
Year: 2009
Tongue: English
Weight: 192 KB
Volume: 26
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-008-9148-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The use of polyethylene glycol-modified

The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma

✍ James C. Yang; Suzanne L. Topalian; Douglas J. Schwartzentruber; David R. Parkin 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 707 KB

Clinical outcome of combined immunothera

Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-α for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report

✍ Hideaki Miyake; Isao Hara; Iori Sakai; Ken-ichi Harada; Taka-aki Inoue; Hiroshi 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 244 KB

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin